Open original FDA record ↗Recall record
- FDA identifier
- Z-1342-2021
- Company in FDA record
- Diasorin Inc.
- FDA record creation date
- Apr 1, 2021
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Potential for system to produce falsely elevated parathyroid hormone (PTH) results from patient samples.
Source facts
- Action
- A Recall notification letter titled, "Urgent DIASORIN CUSTOMER NOTIFICATION LETTER" was sent to consignees on 11/23/2020 via email. The letter instructs the consignee to stop using the LIAISON 1-84 PTH Assay (REF 310630) lot numbers 134909, 134909A, 134909B, and destroy any remaining inventory. They are asked to please complete the bottom portion of the letter and return to DiaSorin to obtain replacement product. The consignee is also instructed to forward the letter to anyone who may be impacted at their facility or anyone these kits have been distributed to outside of the consignee's organization.
- Initiated
- 2020-11-23
- Root cause
- Under Investigation by firm
- Terminated
- 2023-07-06
- Distribution
- Worldwide distribution - US Nationwide in the states of KY, OH, GA, PA, FL and the countries of Canada, Argentina, Bahrain, Bosnia & Herzegovnia, Iraq, Jordan, Morocco, Nepal, Russia, Serbia, Singapore, Taiwan, Thailand, Tunisia, Dubai, Italy, Israel, Brazil, Mexico, Australia, and Bulgaria.
- Recall number
- Z-1342-2021
- Recall status
- Terminated
- CDRH record ID
- 186196
- FDA record created
- 2021-04-01
- Recall event number
- 87501